Ardelyx, Inc. (ARDX)
After hours:
- GlobeNewswire
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting IBSRELA® (tenapanor) will be presented at the 2024 Digestive Disease Week Conference (DDW), to be held May 18-21, 2024, in Washington, D.C. IBSRELA is approved by the U.S. Food and Drug Administration to
- Insider Monkey
Ardelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript
Ardelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript May 2, 2024 Ardelyx, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.13. Ardelyx, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to the Ardelyx […]
- Simply Wall St.
Ardelyx First Quarter 2024 Earnings: Beats Expectations
Ardelyx ( NASDAQ:ARDX ) First Quarter 2024 Results Key Financial Results Revenue: US$46.0m (up 305% from 1Q 2023). Net...
